ArticleAmerican journal of clinical and experimental urology2021

A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin.

Michael Sun et al.PubMed ↗Full text ↗

No numbers read from the abstract.